Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

Why Is Salarius Pharmaceuticals (SLRX) Stock Up 90% Today?

By Josh Enomoto, InvestorPlace Contributor

While Salarius Pharmaceuticals encountered a hiccup in its genomics research, the possibility of new funding may have lifted SLRX stock.

7 Biotech Stocks to Keep on Your Clinical Radar

By Josh Enomoto, InvestorPlace Contributor

Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs.

Trade of the Day: Buy SentinelOne (S) Stock Amid Cybersecurity Carnage

By Josh Enomoto, InvestorPlace Contributor

With endpoint security firm CrowdStrike plunging, the red ink affords an opportunity for SentinelOne and S stock.

Escape the Valley: 3 Smaller Tech Stocks Trump and Vance Are More Likely to Love

By Josh Enomoto, InvestorPlace Contributor

Donald Trump and running mate J.D. Vance could benefit these smaller tech stocks if they win the White House.

QCOM Outlook: Love Qualcomm Stock? Consider Waiting for $140.

By Josh Enomoto, InvestorPlace Contributor

As amazing of an opportunity as Qualcomm stock is, every asset has a reasonable price threshold. For QCOM, it could be $140.

Load More